title: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
abstract: Depletion of immune elements before adoptive cell transfer (ACT) can dramatically improve the antitumor efficacy of transferred CD8+ T cells, but the specific mechanisms that contribute to this enhanced immunity remain poorly defined. Elimination of CD4+CD25+ regulatory T (T reg) cells has been proposed as a key mechanism by which lymphodepletion augments ACT-based immunotherapy. We found that even in the genetic absence of T reg cells, a nonmyeloablative regimen substantially augmented CD8+ T cell reactivity to self-tissue and tumor. Surprisingly, enhanced antitumor efficacy and autoimmunity was caused by increased function rather than increased numbers of tumor-reactive T cells, as would be expected by homeostatic mechanisms. The gammaC cytokines IL-7 and IL-15 were required for augmenting T cell functionality and antitumor activity. Removal of gammaC cytokine-responsive endogenous cells using antibody or genetic means resulted in the enhanced antitumor responses similar to those seen after nonmyeloablative conditioning. These data indicate that lymphodepletion removes endogenous cellular elements that act as sinks for cytokines that are capable of augmenting the activity of self/tumor-reactive CD8+ T cells. Thus, the restricted availability of homeostatic cytokines can be a contributing factor to peripheral tolerance, as well as a limiting resource for the effectiveness of tumor-specific T cells.
authors.affiliation: Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
authors.forename: Luca
authors.initials: L
authors.lastname: Gattinoni
authors.forename: Steven E
authors.initials: SE
authors.lastname: Finkelstein
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Klebanoff
authors.forename: Paul A
authors.initials: PA
authors.lastname: Antony
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Palmer
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Spiess
authors.forename: Leroy N
authors.initials: LN
authors.lastname: Hwang
authors.forename: Zhiya
authors.initials: Z
authors.lastname: Yu
authors.forename: Claudia
authors.initials: C
authors.lastname: Wrzesinski
authors.forename: David M
authors.initials: DM
authors.lastname: Heimann
authors.forename: Charles D
authors.initials: CD
authors.lastname: Surh
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: Nicholas P
authors.initials: NP
authors.lastname: Restifo
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D015551:Autoimmunity / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D045744:Cell Line, Tumor; D016207:Cytokines / Q000276:immunology*; D005260:Female; D008231:Lymphopenia / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014611:Vaccination; D014916:Whole-Body Irradiation
chemical_list: D016207:Cytokines